Syndax (SNDX) provided additional business updates ahead of its presentation at the 44th Annual J.P. Morgan Healthcare conference. Key 2026 Priorities & Anticipated Milestones: Drive Revuforj and Niktimvo net revenue growth; Complete enrollment in MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis; Advance global enrollment in EVOLVE-2 and REVEAL-ND; Initiate RAVEN, a Phase 2 collaborative trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed KMT2Ar patients who would be considered eligible, or fit, for intensive chemotherapy in 2026; Further leadership in menin and CSF-1R inhibition through the publication and presentation of clinical trial data; Initiate a program in 2026 designed to generate proof-of-principle clinical data with revumenib in myelofibrosis
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax, WODA collaborate to launch program to expand access to Revuforj
- Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance
- Promising Growth Prospects for Syndax Pharmaceuticals: Buy Rating Affirmed by Analyst
- Promising Potential of Syndax Pharmaceuticals’ Revuforj in AML Treatment Drives Buy Rating
- Syndax price target raised to $35 from $22 at Barclays